For patients with advanced-stage or poor-prognosis malignant lymphoma, high-dose therapy with peripheral blood progenitor cell (PBPC) support may become a first-line treatment. The duration of severe cytopenia in this setting is inversely related to the number of PBPCs autografted. In a retrospective analysis, we therefore looked for factors influencing the yield of PBpct in 61 patients (16 with high-grade and 29 with low-/intermediategrade non-Hodgkin's lymphoma [NHL], and 16 with Hodgkin's disease) who received cytotoxic chemotherapy and filgrastim (R-metHuG-CSF, 300 pg/d; median, 4.2 pglkgld; range, 2.7 to 6.6 pg/ kg/d; subcutaneously). Sixteen patients had active disease, while 4! 5 were in partial remission (PR) or complete remission (CR) after conventional therapy. A median of three leukaphereses (range, one to 10) resulted in a median of 5.7 x 10" CD34+ cells/kg (range, 0.03 to 31.1 x 10% Previous cytotoxic chemotherapy and irradiation adversely affected the yield of CD34+ cells. Each cycle of chemotherapy is associated with an average decrease o f 0.2 x 10' CD34' cellslkg per leukapheresis in nonirradiated patients, while large-field radiotherapy reduces the collection efficiency by an average YTOTOXIC CHEMOTHERAPY leads to a depletion of lineage-committed hematopoietic progenitor cells, which represent the major target population for the cytokines clinically used.' In contrast, peripheral blood progenitor cells (PBPCs) offer a replacement therapy and are therefore more appropriate to support high-dose therapy than hematopoietic growth factors?*3 PBPCs comprise clonogenic cells at various developmental stages with different capacity of self-renewal and differentiation! At present, most of the mobilization regimens include cytokines such as granulocyte colony-stimulating factor (G-CSF) to increase the number of circulating hematopoietic progenitor cells when administered during steady-state hematopoiesis or after cytotoxic chem~therapy.~.~ The substantial patient-to-patient variation in the yield of PBPCs is a feature common of all mobilization schemes."'o In our attempt to improve blood stem-cell mobilization, we first defined the quantity of PBPCs required for engraftment after high-dose conditioning therapy. We then looked for patient characteristics indicating whether this target quantity is likely to be obtained. The study was performed in a group of 61 patients with malignant lymphoma who were treated in our hospital with cytotoxic chemotherapy and recombinant G-CSF (filgrastim). The blood-derived hematopoietic progenitor cells were collected during cytokine-enhanced leukocyte recovery. Apart from patient-related factors, we found that successful mobilization also critically depends on accurate monitoring of the hematopoietic progenitor cells and their timely collection. During our study, CD34+ assessment emerged as an indispensable method, not only to guide P B X harvesting, but also as a powerful tool to reliably predict a successful outcome following high-dose therapy and autografting.
YTOTOXIC CHEMOTHERAPY leads to a depletion of lineage-committed hematopoietic progenitor cells, which represent the major target population for the cytokines clinically used.' In contrast, peripheral blood progenitor cells (PBPCs) offer a replacement therapy and are therefore more appropriate to support high-dose therapy than hematopoietic growth factors?*3 PBPCs comprise clonogenic cells at various developmental stages with different capacity of self-renewal and differentiation! At present, most of the mobilization regimens include cytokines such as granulocyte colony-stimulating factor (G-CSF) to increase the number of circulating hematopoietic progenitor cells when administered during steady-state hematopoiesis or after cytotoxic chem~therapy.~.~ The substantial patient-to-patient variation in the yield of PBPCs is a feature common of all mobilization schemes." 'o In our attempt to improve blood stem-cell mobilization, we first defined the quantity of PBPCs required for engraftment after high-dose conditioning therapy. We then looked for patient characteristics indicating whether this target quantity is likely to be obtained. The study was performed in a group of 61 patients with malignant lymphoma who were treated in our hospital with cytotoxic chemotherapy and recombinant G-CSF (filgrastim). The blood-derived hematopoietic progenitor cells were collected during cytokine-enhanced leukocyte recovery. Apart from patient-related factors, we found that successful mobilization also critically depends on accurate monitoring of the hematopoietic progenitor cells and their timely collection. During our study, CD34+ assessment emerged as an indispensable method, not only to guide P B X harvesting, but also as a powerful tool to reliably predict a successful outcome following high-dose therapy and autografting.
C MATERIALS AND METHODS

Patients.
Since May 1991, we entered 61 patients (38 males, 23 females) with malignant lymphoma into the study. The median age Blood, Vol 83, No 12 (June 15). 1994: pp 3787-3794 of 1.8 x 10@/kg CD34+ cells. The collection efficiency was also significantly lower in patients with Hodgkin's disease. However, except for one, all had been previously irradiated. In contrast, age, sex, disease status, bone marrow invohrement during mobilization, and the time since the last chemotherapy or radiotherapy were not significantly related to the collection efficiency. Following high-dose conditioning therapy, 42 patients were autografted with filgrastim-mobilized PBPCs. Hematological recovery (neutrophils r0.5 x 10s/L and an unsupported platelet count 220 x 1@/L) within 2 weeks was observed in patients autografted with ~2 . 5 x 10' CD34+ cells/kg. In seven patients, the quantity of CD34+ cells reinfused was below this threshold. They required a median of 17 days (range, 11 to 34) and 31 days (range, 13 to 141) for neutrophil and platelet recovery, respectively. If autografting with PBPCs in malignant lymphoma with poor prognosis is being considered, mobilization and harvesting should be planned early after initial diagnosis to avoid exhaustion of hematopoiesis by cumulative toxicity.
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was 40 years (range, 17 to 58). Sixteen patients had Hodgkin's disease, and 45 had non-Hodgkin's lymphoma (NHL). According to the Working Formulation, there were 16 patients with high-grade NHL and 29 with low-/intermediate-grade NHL. The latter group comprises 24 centrocytic-centroblastic, two centrocytic, and three lymphocytic NHLs, based on the Kiel classification. All patients received conventional chemotherapy such as HAM (cytosine arabinoside 2 g/m' every 12 hours on days 1 and 2, and mitoxantrone 10 mg/m'/d on days 2 and 3; n = 41), DexaEiEAM (dexamethasone 24 mg/d on days 1 to 7, carmustine 60 mg/m' on day 3, etoposide 75 mg/m' on days 4 to 7, cytosine arabinoside 200 mg/m' on days 4 to 7, and melphalan 30 mg/m' on day 3; n = 15). or miscellaneous regimens (n = 5). Subcutaneous administration of filgrastim (RmetHuG-CSF Amgen, Thousand Oaks, CA) was started 24 hours after chemotherapy at 300 pg/d SC (median dose, 4.2 pg/kg/d; range, 2.7 to 6.6 pg/kg/d).
When cytotoxic therapy was initiated, 16 patients had active disease (progressive disease or relapse), while 45 patients were in complete remission (CR) or partial remission (PR). By histopathological examination, 16 patients had bone marrow involvement (two Hodgkin's disease, three high-grade NHL, and 11 low-/intermediate-grade NHL). Pretreatment comprised a median of two different regimens (range, zero to seven) with six cycles (range, zero to 19). Twentynine patients had received previous radiotherapy, such as mantlefield, inverted-Y, total-nodal, or involved-field irradiation. doses ranged between 6 and 50 Gy. The nonhematological toxicity in the 61 patients during cytotoxic chemotherapy and filgrastimsupported PBPC collection did not exceed grade 2 (World Health Organization toxicity grading). Patient characteristics are listed in Table 1 , separately for patients who proceeded to high-dose therapy followed by PBPC autografting and patients not included in this transplantation program.
The study was conducted under the ethical guidelines of the Joint Committee on Clinical Investigation of the University of Heidelberg. Informed consent was obtained from each patient. The cutoff date of this report is September 30, 1993.
Collection of PBPCs and cryopreservation. Harvesting was performed with a Fenwal CS 3000 (Baxter Deutschland, Munchen, Germany). PBPC collection was started after a white blood cell (WBC) count greater than 1 X 109/L was reached. For the first 12 patients, a target quantity of 0.4 X 109/kg total nucleated cells (TNCs) was envisaged. Recognizing the predictive quality of this parameter, the collection was thereafter monitored by CD34+ cell assessment, aiming at 5.0 X lo6 CD34' cellsikg body weight.
Individual peak values of CD34+ cells in the peripheral blood for the first 12 patients are derived from measurements on days of leukaphereses. From then on, daily measurements (except for weekends) were available. Our evaluation of circulating hematopoietic progenitor cells is based on a total of 229 peripheral blood samples. For each leukapheresis, 10 L blood were processed at a flow rate of 50 to 70 mL/min. The apheresis product of a 50-mL cell suspension was mixed with the same volume of minimal essential medium (MEM) containing 20% dimethylsulfoxide (DMSO; Merck, Darmstadt, Germany). The final 100-mL cell suspension was transferred into freezing bags (Delmed, New Brunswick, NJ) and frozen to -100°C with a computer-controlled cryopreservation device (Cryoson BV-6; Cryoson Deutschland, Germany). The frozen cells were transferred into liquid-phase nitrogen and stored at -196°C.
HAAS ET AL
Clonogenic assay for hematopoietic progenitor cells. The concentration of hematopoietic progenitor cells in each single leukapheresis product and in the peripheral blood was assessed using a semisolid clonogenic culture assay (Terry Fox Laboratories, Vancouver, Canada). The culture medium consisted of 30% fetal calf serum, 10% medium conditioned by phytohemagglutinin-stimulated leukocytes (PHA-LCM), 1 IU recombinant human erythropoietin, 5 X mol 2-mercaptoethanol, and 0.9% methylcellulose. A quantity of 2 x I05/mL mononuclear cells were plated in duplicate and incubated at 37°C and 5% COz in humidified atmosphere. After 14 days, colonies were scored using an inverted microscope.
Immunofuorescence staining and jow cytometry. For immunofluorescence analysis, 20 pL of whole blood or 1 X lo6 mononuclear cells were incubated for 30 minutes at 4°C with the fluorescein isothiocyanate (FITC)-conjugated monoclonal antibody HPCA-2 (CD34) (Becton-Dickinson, Heidelberg, Germany). The cells were analyzed with a Becton-Dickinson FACScan with a 2-W argon ion laser as a light source. Excitation was allowed at 488 nm and fluorescence was measured at 530 nm. We used a forward-scatter versus CD45 fluorescence dot plot to discriminate between the smallest lymphohematopoietic cell population and erythrocytes or debris. The CD34+ cell population was analyzed in a fluorescence-l versus sidescatter characteristics (SSC) dot plot. The SSC delineates the granularity of cells. Only cells with lymphoid or lymphoblastoid characteristics (low SSC) were counted as CD34+ cells and further assessed for their forward-scatter characteristics (FSC), which delineate the cell size. The percentage of CD34+ cells was calculated as follows: % = (CD34+ cells/CD45+ cells) X 100. To evaluate CD34+ cells/ pL of peripheral blood, the percentage of CD34' cells was multiplied by the WBC count.
Pretransplantation conditioning regimen and intensive care posttransplant. The pretransplantation conditioning therapy was totalbody irradiation (TBI; 14.4 Gy, hyperfractionated over 4 days) and cyclophosphamide (200 mgikg over 4 days) in 23 patients, while six patients received the BEAM protocol (carmustine 300 mglm', etoposide 1200 mg/m2, cytosine arabinoside 800 mg/m', and melphaIan 140 mg/m'), and 13 patients were treated with the CBV regimen (cyclophosphamide 6.8 g/m', etoposide 1,600 mg/m2, and carmustine 450 mglm'). All patients had prophylactic gut decontamination. Antibiotic combination therapy was administered for fever greater than 38.5"C, and amphotericin-B was added for documented fungal infection or persistent fever. A platelet count greater than 20 X I O 9 L was maintained by HLA-A/-B-matched platelet transfusions, and packed red blood cells were given when the hemoglobin was less than 8 g/dL.
Statistical analysis. The clinical and laboratory data of the patients were analyzed according to standard statistical methods using a commercially available computer program (Statworks, Cricket Software, Philadelphia, PA). The relationship between the different hematological parameters of the peripheral blood and leukapheresis products was estimated by simple linear regression and correlation analysis. The collection efficiency for each patient is calculated as CD34' cellskg harvested per leukapheresis. This parameter was used to evaluate the influence of particular patient characteristics. For numerical variables, we formed two groups of equal size using the median value. To assess for statistical significance, the MannWhitney U test was applied. A significance level of P less than .05 was chosen. lo9/ L). The individual peak values occurred as early as 12 days after the start of chemotherapy and spread over a 2-log range between 2/pL and 619/pL (median, U.l/pL). In general, high rebound levels were observed in patients with an early and brisk leukocyte recovery. Regression analysis showed a close relationship between CD34+ cells and clonogenic progenitor cells. For colony-forming units-granulocytemacrophage (Cm-GM) and burst-forming units-erythrocytes (BFU-E), the correlation coefficient was 0.71 and 0.72 ( P < .001), respectively.
RESULTS
Circulating hematopoietic progenitor cells.
Blood stem-cell collection.
PBPC collections were started at a median WBC count of 6.4 X 109/L (range, 1.0 to 43.9 X lo9&). Autografts were obtained with a median of three leukaphereses (range, one to 10) and contained CD34+ cells in a range between 0.03 X 1O'kg and 31.1 X 106kg (median, 5.7 X 106kg). The number of leukaphereses performed and the quantity of CD34+ cellskg harvested were inversely related ( r = -.38, P < .Ol), demonstrating that low yields did not result from early cessation of PBPC collection.
What is a meaningful target number of CD34' cells for harvesting? As we will show, this question could be answered retrospectively: autografting of at least 2.5 X IO'kg CD34+ cells rapidly restored hematopoiesis after high-dose conditioning therapy. This value therefore became an important figure. We found that 60 single leukapheresis products from 34 patients contained this quantity sufficient for engraftment. Moreover, it was predictable by the number of circulating CD34' cells on the morning of the collection day. As demonstrated by the regression analysis in Fig 1, a level of 50/pL CD34+ cells in the peripheral blood indicates that 2.5 X IO6 CD34+ cellskg are likely to be obtained with a single leukapheresis. In contrast, 15 patients had total harvests containing less than 2.5 X lo6 CD34' cellskg, although a median of six leukaphereses (range, one to 10) had been performed.
Patient characteristics and yield of PBPCs. We identified previous cytotoxic chemotherapy and irradiation as the major variables adversely affecting the yield of filgrastimmobilized PBPCs (Table 2 ). In 32 patients who had no previous irradiation, the number of CD34+ cells harvested per leukapheresis decreased by an average of 0.2 X 10'kg with each cycle of chemotherapy. This value is derived from a correlation analysis and represents the slope of the regression curve in Fig 2A. The same analysis was then performed for the 29 patients who had been previously irradiated. The resulting regression curve had a similar slope to the one in nonirradiated patients (Fig 2B) . We thus superimposed both graphs and determined the intercepts on the ordinate ( Fig  2C) . The difference reflects a radiotherapy-associated decrease in the collection efficiency of 1.8 X 106kg CD34' cells. The three irradiated patients who presented with exceptionally high collection efficiencies above 4.0 X lO%g had received involved-field radiotherapy to the mediastinum or left axilla, with total doses not exceeding 30 Gy. The other The correlation analysis is based on a total of 142 paired samples and performed after logarithmic transformation. As reflected by the regression curve, a CD34' cell count of at least 5WpL is highly predictive for a yield greater than 2.5 x 10' CD34+ cellslkg, sufficient for grafting with this single product.
26 patients had undergone large-field irradiation, such as mantle-field, total-nodal, or abdominal irradiation. The site of radiotherapy, ie, above or below the diaphragm, was not related to the collection efficiency.
It is of note that patients with Hodgkin's disease had a significantly lower collection efficiency compared with those with NHL. However, except for one, all had been irradiated, which does not allow the assessment of diagnosis as an independent variable. Shorter time intervals to previous cytotoxic therapy tended to be associated with decreased collection efficiencies, although not reaching the level of statistical significance.
The following patient characteristics were not related to the collection efficiency: age, sex, and disease status at mobilization. Since marrow infiltration was only present in two patients with Hodgkin's disease, bone marrow involvement at the time of PBPC mobilization was only addressed in the 45 NHL patients. Those with bone marrow involvement had, on average, an almost twofold higher collection efficiency. However, because of the wide patient-to-patient variation within this group, the difference was not statistically significant. The effect of the mobilization regimens was not assessed, because the majority of patients with Hodgkin's disease received DexaBEAM, and almost all NHL patients were treated with HAM.
Autografting with Jilgrastim-mobilized PBPCs after highdose therapy.
Forty-two patients were included into the transplantation protocol (Table 3) . The decision to proceed with PBPC-supported high-dose therapy was independent of the CD34+ cell harvest. High-dose cyclophosphamide and hyperfractionated TB1 were used in 23 patients, while six .
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x Collection efficiency is given as CD34+ cells x 106/kg harvested t A significance level of P .05 was chosen.
* For numerical variables, two groups of equal size were formed using the median value. § Compared with patients with non-Hodgkin's lymphoma (NHL), the collection efficiency in Hodgkin's disease (HD) was significantly lower. Because all patients with HD except for one had previous irradiation, diagnosis was not addressed as independent variable. per leukapheresis.
'l Active disease comprises progressive disease and relapse.
Bone marrow (BM) involvement was only addressed in the 45
NHL patients, since marrow involvement was only present in two patients with HD.
patients received the BEAM protocol and 13 patients were treated with the CBV regimen. Thirty-five patients were autografted with at least 2.5 X lo6 CD34+ cellskg and achieved platelet counts greater than 20 X 109/L within 14 days, except for one patient who required 17 days (Fig 3) . In these patients, no difference was found whether high-dose therapy included TB1 or not (Fig 4) .
In contrast, seven patients received autografts containing less than 2.5 X lo6 CD34' cellskg. The time required for hematological reconstitution is given in Table 4 . The patient with Hodgkin's disease who received 0.03 X lo6 CD34+ cellskg after high-dose CBV therapy belongs to the group of the first 12 patients transplanted. The decision to use the PBPC autograft was based on the TNC count, which was close to the threshold of 0.4 X 109kg. Platelet reconstitution to an unsubstituted count of greater than 20 X 109L lasted 141 days, while the course posttransplantation was otherwise uneventful. No transplantation-related death occurred, and the toxicity in the 42 patients autografted was moderate, which is best reflected by the parameters listed in Table 5 .
The seven patients transplanted with low CD34+ cell counts received antibiotics 6 days longer on average and required approximately three times more platelet transfusions. Their days of fever greater than 38.5"C compared with that of the patients autografted with more than 2.5 X 106/CD34+ cells/ With a median follow-up duration of 8 months (range, 2 to 25), 32 patients are alive in remission, including four patients in the low CD34+ cell group. With a longest observation time of 25 months, no graft failure has been observed.
Reasons for exclusion from PBPC-supported high-dose therapy. Nineteen patients were not included into this PBPC transplantation program. The majority of patients were not eligible because of progressive disease or relapse after mobilization therapy. These were one patient with Hodgkin's disease and eight patients with high-grade NHL. One patient with low-/intermediate-grade NHL was excluded after he developed severe thrombocytopenia resulting from abdominal irradiation, whereas two patients with low-/ intermediate-grade NHL were included in a, at that time, concurrent transplantation protocol using immunopurged bone marrow. Collection of PBPCs served as back-up for these patients. One patient with Hodgkin's disease and a low CD34+ content in the PBPC autograft (0.47 X 106kg) was transplanted using both PBPCs and bone marrow. In 5 patients the follow-up after PBPC mobilization was too short.
DISCUSSION
kg.
This report may help to design protocols for high-dose therapy with PBPC support in malignant lymphoma. Extending our previous observation in a study of 10 patients," we now demonstrate a threshold quantity of 2.5 X lo6 CD34+ cellskg required for engraftment after high-dose conditioning therapy. The moderate treatment-related toxicity reflects the fact that the majority of patients had a rapid hematological recovery, which was independent of the inclusion of TB1 in the high-dose therapy regimen. This finding argues against a specific regimen-related priming effect necessary for engraftment." Cytotoxic conditioning may not be needed at all, as recently demonstrated by Stewart et a1 in an animal m0de1.I~ Of note, seven patients were autografted with less than 2.5 X lo6 CD34+ cellskg, including one patient receiving a TBI-containing regimen. Autochthonous hematopoietic recovery may explain long-term reconstitution, at least in the patients who were treated with high-dose chemotherapy alone. This view is supported by the data of Laporte et al,I4 who demonstrated hematological reconstitution after high-dose therapy with BEAM and granulocytemacrophage CSF (GM-CSF) support. Given a benefit of dose-escalated regimens, autografting of patients with low numbers of CD34' cells might be justified following pretransplant therapy without TBI. This requires acceptance of an increased risk of treatment-related complications, more supportive therapy, and a longer hospitalization.
Traditionally, the number of mononuclear cells or clonogenic progenitor cells served to characterize the cellular composition of an autograft. Suggestions were made for CFU-GM and varied among centers, reflecting the differences in culture techniques and in the patient populations 
Number of Previous Chemotherapy Cycles
~tudied.'~ The results of these assays are only available after 14 days of culture and therefore are not suitable for monitoring PBPC collection. They can still serve as a read-out of the proliferative capacity of clonogenic progenitor cells. Besides the quality control for freezing and thawing, their relevance in the setting of clinical transplantation becomes questionable.
The importance of CD34+ cell assessment for PBPC mobilization and autografting was first noted by Siena et al. L6 With the availability of directly labeled monoclonal antibod- CD34+ cells below this margin. Only scant data are available how to proceed in patients like these.
In a study by Kotasek et al, an increase from 4 to 7 g/ m* cyclophosphamide administered without growth factor resulted in a doubling of Cm-GM harvested." This approach is different from our strategy using polychemotherapy for PBPC mobilization. In a few cases, we have postponed progenitor-cell collection for at least 1 month to resume filgrastim administration from steady-state hematopoiesis. This approach was not successful in improving the collection efficiency. The possibility of autografting bone marrow in addition to PBPCs in patients with a low CD34+ yield appears to have no promise in the light of clinical studies showing no difference in reconstitution time between PBPCs alone and PBPCs combined with bone marrow." Moreover, nine of our 15 patients with low CD34+ cell yields had undergone abdominal irradiation, excluding them from marrow harvesting. Whether an increase in the dose of filgrastim after chemotherapy may lead to a higher mobilization outcome is currently under investigation. The rationale for this approach is to overcome a negative feedback mechanism exerted by an increasing number of neutrophils after hematological reconstitution. They can reduce the bioavailability of G-CSF via binding to high-affinity receptors. '" We found that patient characteristics such as age, sex, disease status at mobilization, or bone marrow involvement at the time of mobilization were not related to the collection efficiency of filgrastim-mobilized PBPCs. Although statistically not significant, it is remarkable that 14 patients with NHL and bone marrow involvement at the time of mobilization had a higher collection efficiency than 3 1 patients without residual disease. Bone marrow involvement was confined to patients with low and intermediate histology. One could speculate whether lymphomatous marrow infiltration is associated with an increased likelihood of hematopoietic progenitor cells to traffic in the peripheral blood.
The literature provides only few and controversial data on this subject. Shepherd et a1 first reported that bone marrow involvement and previous chemotherapy within 12 months were associated with decreased mobilization." We also found that collection efficiencies tended to be higher in patients with a longer time interval since the last cytotoxic therapy, which suggests a time-dependent recovery of hematopoietic progenitor cells from cytotoxic effects. Data from Kotasek et a1 at the same center then suggested that bone marrow infiltration and the number of premobilization chemotherapeutic cycles did not affect the ability to collect sufficient quantities of CFU-GM.** From our analysis, previous chemotherapy and radiotherapy unequivocally emerged as major factors adversely affecting the collection efficiency. To quantify the effect, we performed separate regression analyses for patients with and without radiotherapy. The dose-intensity or composition of the cytostatic regimens could not be taken into account. The substantial radiotherapy-related decrease of the harvest is of particular relevance for patients with advanced-stage Hodgkin's disease, because most treatment protocols for these patients include extended-or involved-field irradiation.*' High-risk patients with poor prognostic factors such as bulky mediastinal disease and lung or pleura involvement should therefore be considered for PBPC collection before hematopoiesis is exhausted. 24 Finally, it must also be considered that autografts may contain cells of the malignant clone. Assessment for residual disease is therefore required, provided that adequate tech- 
